Key result
CYP2C19 genotyping reveals ~30% of Turkish cardiac patients on clopidogrel are intermediate metabolizers.
Why the study?
CYP2C19 variations affect clopidogrel response, and determining population-specific variant frequencies helps predict clopidogrel efficacy and risks despite lacking universal pharmacogenetic testing guidelines.
What is the distribution of CYP2C19 gene polymorphisms in Turkish cardiac patients prescribed clopidogrel?
Population
54 Turkish cardiac patients prescribed clopidogrel
Design
Observational genetic analysis
Authors
Loading...
Variant CYP2C19 phenotypes common in Turkish patients; extends prevalence data but leaves clinical utility of testing open.
Cross-Sectional (n=54)
What is the distribution of CYP2C19 gene polymorphisms in Turkish cardiac patients prescribed clopidogrel?
A high frequency of intermediate, rapid, and ultra-rapid CYP2C19 metabolizers exists among Turkish cardiac patients, highlighting the potential utility of pharmacogenetic testing for clopidogrel therapy.
Duman et al. (2021) conducted a cross-sectional in Cardiac patients prescribed clopidogrel (n=54). CYP2C19 genotyping was evaluated on Distribution of CYP2C19 gene polymorphisms. CYP2C19 genotyping in 54 Turkish cardiac patients prescribed clopidogrel identified 29.63% as intermediate, 27.78% as rapid, and 1.85% as ultra-rapid metabolizers.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: